.After increasing $170 thousand back in February, metabolic disease-focused BioAge Labs has actually submitted to debut on the public market.The Eli Lilly-partnered biotech wish to list on the Nasdaq under the symbolic representation "BIOA," according to files submitted with the Securities as well as Substitution Compensation. The business has actually not openly shared an anticipated financial quantity for the offering.The clinical-stage provider touts lead applicant azelaprag, an orally delivered tiny molecule slated to enter period 2 screening in combo with semaglutide-- marketed through Novo Nordisk under brand name Wegovy for fat burning-- in the 1st one-half of following year. Semaglutide is likewise marketed as Ozempic and also Rybelsus through Novo for diabetic issues.
Apelin receptor agonist azelaprag is designed to combine well with GLP-1 medications, improving weight management while keeping muscular tissue mass. The investigational medication was discovered to be well-tolerated amongst 265 individuals throughout eight phase 1 tests, depending on to BioAge.Formerly, BioAge amassed the support of Lilly to run a test integrating azelaprag along with the Huge Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is actually industried for diabetes as Mounjaro as well as Zepbound for weight management. The companions are actually presently administering a phase 2 trial of azelaprag as well as tirzepatide, along with topline outcomes assumed in the third quarter of 2025.The biotech is also organizing an insulin sensitiveness proof-of-concept trial evaluating azelaprag as a monotherapy in the initial half of following year to support prospective sign growth. On top of that, the business considers to talk to the FDA for consent in the second fifty percent of 2025 to introduce human screening for an NLRP3 inhibitor targeting metabolic diseases and also neuroinflammation.BioAge's expected move to the public market adheres to a small uptick in organized biotech IPOs coming from Bicara Therapeutics and also Zenas Biopharma. Zooming out, the latest IPO garden is actually a "blended photo," along with high-quality companies still debuting on everyone markets, only in decreased varieties, according to PitchBook.